Abbott Laboratories (NYSE:ABT) is scheduled to announce Q2 earnings results on Thursday, July 18th, before the market opens.
Analysts expect a profit of $1.10 per share (+1.9% Y/Y) on revenue of $10.37B (+3.7% Y/Y).
“We expect a good Q2, although we believe FX is slightly worse than a guide. We believe underlying strength supports a modest top and bottom-line beat, and we expect a full-year EPS guidance raise at least in line with the Q2 beat,” Wells Fargo Research said in a statement.
Over the last 2 years, ABT has beaten EPS estimates 100% of the time and has beaten revenue estimates 100% of the time.
Over the last 3 months, EPS estimates have seen 4 upward revisions and 8 downward. Revenue estimates have seen 1 upward revision and 15 downward.
According to SA analyst Stephen Simpson, “Abbott could outperform in this upcoming quarter, and my expectations for the next three years are a little above Street averages. While I do have my issues and concerns with Abbott, the company still has a strong presence across cardiology and diabetes that should continue to generate good growth.”
The company has a Hold rating under SA quant ratings, while Wall Street Analysts recommend it as a Buy.
YTD, the stock has fallen 4.4%
